Certified Nurse-Midwife Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Sharon Harkey

Advanced Practice Midwife La Jolla, CA Certified Nurse-Midwife

NPI 1043711369 CMS profile 11175682

9850 Genesee Ave Ste 600, La Jolla, CA 92037

Open in the dashboard

General payments

$1,197

45 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sharon Harkey of La Jolla, CA is reported in the CMS Open Payments database as having received $1,197 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Advanced Practice Midwife profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $490 20
2024 General $461 15
2023 General $194 8
2022 General $52 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharon Harkey
  • Advanced Practice Midwife median
  • Middle half of Advanced Practice Midwife
  • National median

In program year 2025, general payments to Sharon Harkey were reported at $490. Among 4,127 Advanced Practice Midwife profiles paid that year, the median was $71 and the middle half received between $28 and $161.

Show as a table
Year Sharon Harkey Advanced Practice Midwife median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $57 $22–$142 $132
2022 $52 $61 $23–$157 $149
2023 $194 $68 $26–$167 $160
2024 $461 $63 $25–$142 $164
2025 $490 $71 $28–$161 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Astellas Pharma US Inc $322 11 payments
  2. Mayne Pharma Inc. $294 6 payments
  3. Biogen, Inc. $160 7 payments
  4. Evofem Biosciences, Inc. $120 7 payments
  5. Millicent US Inc $52 3 payments
  6. Hologic, LLC $47 2 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $47 2 payments
  8. Daiichi Sankyo Inc. $31 1 payment
  9. AbbVie, Inc. $29 1 payment
  10. Myovant Sciences Inc. $23 1 payment
  11. Other $72 4 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,197 45 payments
Products named General payments · program years 2022–2025
  1. Veozah $322 11 payments
  2. Zurzuvae $160 7 payments
  3. ANNOVERA Contraception $124 1 payment
  4. NEXTSTELLIS $124 1 payment
  5. ANNOVERA Contraceptive $120 1 payment
  6. Mirena $47 2 payments
  7. Kyleena $47 2 payments
  8. Phexxi $34 2 payments
  9. Phexx $34 2 payments
  10. Solosec $34 2 payments
  11. Other $284 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

80

Median for Certified Nurse Midwife: 28

Drug cost

$6,684

Median for Certified Nurse Midwife: $1,314

Branded share of claims

52.5%

Median for Certified Nurse Midwife: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 38 $3,878
Estradiol (Twice Weekly) Estradiol Brand 11 $1,314
Progesterone Progesterone, Micronized Brand 18 $786
Valacyclovir Valacyclovir Hcl Brand 13 $706

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,212 Part D prescribers listed as Certified Nurse Midwife; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$2,337

Medicare's payments for the services billed

Medicare patients

37

Average age 69

Services billed

39

37 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 49%
Arthritis 38%
Osteoporosis 30%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $155
$155 — —
INJECTAFER
  • Daiichi Sankyo Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record